JOP20170046B1 - صيغة جونادوتروبين سائلة مستقرة - Google Patents
صيغة جونادوتروبين سائلة مستقرةInfo
- Publication number
- JOP20170046B1 JOP20170046B1 JOP/2017/0046A JOP20170046A JOP20170046B1 JO P20170046 B1 JOP20170046 B1 JO P20170046B1 JO P20170046 A JOP20170046 A JO P20170046A JO P20170046 B1 JOP20170046 B1 JO P20170046B1
- Authority
- JO
- Jordan
- Prior art keywords
- stable liquid
- formulation
- liquid gonadotropin
- gonadotropin formulation
- stabilization
- Prior art date
Links
- 102000006771 Gonadotropins Human genes 0.000 title abstract 3
- 108010086677 Gonadotropins Proteins 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000002622 gonadotropin Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000007788 liquid Substances 0.000 title 1
- 230000006641 stabilisation Effects 0.000 abstract 2
- 238000011105 stabilization Methods 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 229940094892 gonadotropins Drugs 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
يتعلق الاختراع الحالي بصفة عامة بتثبيت صيغ منبهة للغدد التناسلية، وبخاصة بصيغ سائلة من منبهات الغدد التناسلية. يتحقق التثبيت بواسطة توليفة معينة من السواغات، يفضل الأرجينين والميثيونين. في نموذج مفضل، لا تشتمل الصيغة على محلول منظم.andnbsp;
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1603280.7A GB201603280D0 (en) | 2016-02-24 | 2016-02-24 | Stable liquid gonadotropin formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20170046B1 true JOP20170046B1 (ar) | 2021-08-17 |
Family
ID=55806922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2017/0046A JOP20170046B1 (ar) | 2016-02-24 | 2017-02-19 | صيغة جونادوتروبين سائلة مستقرة |
Country Status (36)
Country | Link |
---|---|
US (3) | US10792334B2 (ar) |
EP (3) | EP4257149A3 (ar) |
JP (3) | JP6932710B2 (ar) |
KR (1) | KR20180114178A (ar) |
CN (2) | CN113398250B (ar) |
AR (1) | AR107782A1 (ar) |
AU (2) | AU2017222292B2 (ar) |
BR (1) | BR112018015166A2 (ar) |
CA (1) | CA3012759A1 (ar) |
CL (1) | CL2018001984A1 (ar) |
CO (1) | CO2018007810A2 (ar) |
DK (2) | DK3419595T3 (ar) |
EA (1) | EA036383B1 (ar) |
ES (2) | ES2966262T3 (ar) |
FI (1) | FI3791860T3 (ar) |
GB (1) | GB201603280D0 (ar) |
HR (2) | HRP20231477T1 (ar) |
HU (2) | HUE064432T2 (ar) |
IL (1) | IL260626B2 (ar) |
JO (1) | JOP20170046B1 (ar) |
LT (2) | LT3419595T (ar) |
MA (2) | MA43686B1 (ar) |
MD (2) | MD3419595T2 (ar) |
MX (1) | MX2018010201A (ar) |
MY (1) | MY193138A (ar) |
PH (1) | PH12018501688A1 (ar) |
PL (2) | PL3419595T3 (ar) |
PT (2) | PT3791860T (ar) |
RS (2) | RS64929B1 (ar) |
SG (1) | SG11201806140SA (ar) |
SI (2) | SI3791860T1 (ar) |
TN (1) | TN2018000284A1 (ar) |
TW (1) | TWI755377B (ar) |
UA (1) | UA123107C2 (ar) |
WO (1) | WO2017144659A1 (ar) |
ZA (1) | ZA201804944B (ar) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201603280D0 (en) | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
WO2019164765A1 (en) * | 2018-02-26 | 2019-08-29 | Slayback Pharma Llc | Ready-to-use dexmedetomidine compositions |
WO2020071912A1 (en) * | 2018-10-02 | 2020-04-09 | Innocore Technologies B.V. | Extended release formulations of human chorionic gonadotropin (hcg) |
CN112451652A (zh) * | 2020-12-07 | 2021-03-09 | 苏州智核生物医药科技有限公司 | 一种重组人促甲状腺素注射液 |
WO2022197963A1 (en) * | 2021-03-19 | 2022-09-22 | Pfizer Inc. | Long-acting growth hormone compositions |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0803832A3 (en) | 1996-02-28 | 2000-05-31 | Hitachi, Ltd. | Card holder-type balance display |
TW518235B (en) * | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
WO2000004913A1 (en) * | 1998-07-23 | 2000-02-03 | Eli Lilly And Company | Fsh and fsh variant formulations, products and methods |
BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
KR101105871B1 (ko) * | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
GB0700523D0 (en) | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
EA019432B1 (ru) * | 2007-11-01 | 2014-03-31 | Мерк Сероно С.А. | Жидкие композиции lh |
US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
NZ586588A (en) | 2008-02-08 | 2012-10-26 | Biogenerix Ag | Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol |
TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
RU2553375C2 (ru) | 2010-02-12 | 2015-06-10 | Интас Биофармасьютикалс Лимитед | Жидкий состав фолликулостимулирующего гормона |
WO2011108010A2 (en) | 2010-03-05 | 2011-09-09 | Intas Biopharmaceuticals Limited | A thermostable liquid formulation of gonadotropins |
EP2417982A1 (en) | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
CN105658201A (zh) * | 2013-11-12 | 2016-06-08 | 卡迪拉保健有限公司 | 促性腺激素的制剂 |
GB201603280D0 (en) * | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
-
2016
- 2016-02-24 GB GBGB1603280.7A patent/GB201603280D0/en not_active Ceased
-
2017
- 2017-02-19 JO JOP/2017/0046A patent/JOP20170046B1/ar active
- 2017-02-23 TW TW106106132A patent/TWI755377B/zh active
- 2017-02-24 ES ES20202758T patent/ES2966262T3/es active Active
- 2017-02-24 MA MA43686A patent/MA43686B1/fr unknown
- 2017-02-24 ES ES17707527T patent/ES2862193T3/es active Active
- 2017-02-24 MD MDE20190039T patent/MD3419595T2/ro unknown
- 2017-02-24 CN CN202110585922.3A patent/CN113398250B/zh active Active
- 2017-02-24 EP EP23194814.2A patent/EP4257149A3/en active Pending
- 2017-02-24 PL PL17707527T patent/PL3419595T3/pl unknown
- 2017-02-24 PT PT202027587T patent/PT3791860T/pt unknown
- 2017-02-24 SI SI201731448T patent/SI3791860T1/sl unknown
- 2017-02-24 AR ARP170100475A patent/AR107782A1/es unknown
- 2017-02-24 AU AU2017222292A patent/AU2017222292B2/en active Active
- 2017-02-24 SI SI201730666T patent/SI3419595T1/sl unknown
- 2017-02-24 MX MX2018010201A patent/MX2018010201A/es unknown
- 2017-02-24 SG SG11201806140SA patent/SG11201806140SA/en unknown
- 2017-02-24 MA MA52595A patent/MA52595B1/fr unknown
- 2017-02-24 JP JP2018544561A patent/JP6932710B2/ja active Active
- 2017-02-24 FI FIEP20202758.7T patent/FI3791860T3/fi active
- 2017-02-24 EA EA201891905A patent/EA036383B1/ru not_active IP Right Cessation
- 2017-02-24 WO PCT/EP2017/054325 patent/WO2017144659A1/en active Application Filing
- 2017-02-24 HU HUE20202758A patent/HUE064432T2/hu unknown
- 2017-02-24 TN TNP/2018/000284A patent/TN2018000284A1/en unknown
- 2017-02-24 LT LTEP17707527.2T patent/LT3419595T/lt unknown
- 2017-02-24 UA UAA201809497A patent/UA123107C2/uk unknown
- 2017-02-24 RS RS20231172A patent/RS64929B1/sr unknown
- 2017-02-24 DK DK17707527.2T patent/DK3419595T3/da active
- 2017-02-24 MY MYPI2018001301A patent/MY193138A/en unknown
- 2017-02-24 KR KR1020187027128A patent/KR20180114178A/ko unknown
- 2017-02-24 HR HRP20231477TT patent/HRP20231477T1/hr unknown
- 2017-02-24 EP EP17707527.2A patent/EP3419595B1/en active Active
- 2017-02-24 PL PL20202758.7T patent/PL3791860T3/pl unknown
- 2017-02-24 CN CN201780013134.9A patent/CN108883061B/zh active Active
- 2017-02-24 DK DK20202758.7T patent/DK3791860T3/da active
- 2017-02-24 EP EP20202758.7A patent/EP3791860B1/en active Active
- 2017-02-24 MD MDE20210250T patent/MD3791860T2/ro unknown
- 2017-02-24 HU HUE17707527A patent/HUE053492T2/hu unknown
- 2017-02-24 RS RS20210361A patent/RS61604B1/sr unknown
- 2017-02-24 LT LTEP20202758.7T patent/LT3791860T/lt unknown
- 2017-02-24 BR BR112018015166A patent/BR112018015166A2/pt active Search and Examination
- 2017-02-24 CA CA3012759A patent/CA3012759A1/en active Pending
- 2017-02-24 PT PT177075272T patent/PT3419595T/pt unknown
- 2017-02-24 US US16/079,428 patent/US10792334B2/en active Active
-
2018
- 2018-07-17 IL IL260626A patent/IL260626B2/en unknown
- 2018-07-23 ZA ZA2018/04944A patent/ZA201804944B/en unknown
- 2018-07-23 CL CL2018001984A patent/CL2018001984A1/es unknown
- 2018-07-27 CO CONC2018/0007810A patent/CO2018007810A2/es unknown
- 2018-08-08 PH PH12018501688A patent/PH12018501688A1/en unknown
-
2020
- 2020-09-14 US US17/020,279 patent/US11666635B2/en active Active
-
2021
- 2021-03-03 HR HRP20210367TT patent/HRP20210367T1/hr unknown
- 2021-08-18 JP JP2021133422A patent/JP2021191760A/ja active Pending
-
2022
- 2022-01-05 AU AU2022200027A patent/AU2022200027A1/en active Pending
-
2023
- 2023-04-21 US US18/138,000 patent/US20230372447A1/en active Pending
- 2023-09-15 JP JP2023150308A patent/JP2023164573A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501688A1 (en) | Stable liquid gonadotropin formulation | |
PH12017501956A1 (en) | Compositions of obeticholic acid and methods of use | |
CL2018000320A1 (es) | Coadyuvantes basados en aceite (divisional de solicitud 201600650) | |
MX2017017157A (es) | Composiciones de bebida lista para beber estables que comprende agentes activos lipofilos. | |
MD20170070A2 (ro) | Derivaţi de chinazolină utilizaţi în tratamentul HIV | |
MY187047A (en) | Selective pyy compounds and uses thereof | |
CR20160499A (es) | Composiciones estables de yodo no en complejo y métodos de uso | |
EA201890343A1 (ru) | Быстродействующие инсулиновые композиции | |
MX2021015789A (es) | Reduccion de la viscosidad de formulaciones farmaceuticas. | |
MX2017007178A (es) | Formulaciones liquidas estables de virus de vacuna. | |
AR098168A1 (es) | Formulación estable de insulina glulisina | |
EA201991798A1 (ru) | Стабильные при хранении составы | |
CL2019002733A1 (es) | Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico. | |
TW201613557A (en) | Stable aqueous recombinant protein formulations | |
MX2019011545A (es) | Composiciones celulares y de andamio inyectables. | |
PH12015502082A1 (en) | Improved stability and potency of hemagglutinin | |
CL2019002729A1 (es) | Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico. | |
SG11201805123XA (en) | Pharmaceutical composition comprising anti-human tslp receptor antibody | |
MX2019010330A (es) | Formulaciones con mejora de la estabilidad. | |
PH12018502089A1 (en) | Pharmaceutical composition of dapagliflozin | |
EA201691792A1 (ru) | Фармацевтические составы на основе вилдаглиптина | |
GEP20237486B (en) | Formulations of copanlisib | |
MX2017013879A (es) | Composiciones que comprenden anakinra. | |
CL2016000542A1 (es) | Composición que comprende hidroxipropil quitosano junto con excipientes y/o adyuvantes farmacéuticamente aceptables; útil en el tratamiento de la onicomicosis. | |
UA106905U (uk) | Фармацевтична композиція |